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Abstract
Background
\Anticoagulation is used for stroke prophylaxis in non-valvular atrial fibrillation, amongst
other by use of the vitamin K antagonist, warfarin. Quality in warfarin therapy is often sum-
marized by the time patients spend within the therapeutic range (percent time in therapeutic
range, TTR). The correlation between TTR and the occurrence of complications during war-
farin therapy has been established, but the influence of patient characteristics in that respect
remains undetermined. The objective of the present papers was to examine the association
between mean TTR and complication rates with adjustment for differences in relevant
patient cohort characteristics.
Methods
A systematic literature search was conducted in MEDLINE and Embase (2005–2015) to
identify eligible studies reporting on use of warfarin therapy by patients with non-valvular
atrial fibrillation and the occurrence of hemorrhage and thromboembolism. Both randomized
controlled trials and observational cohort studies were included. The association between
the reported mean TTR and major bleeding and stroke/systemic embolism was analyzed by
random-effects meta-regression with and without adjustment for relevant clinical cohort
characteristics. In the adjusted meta-regressions, the impact of mean TTR on the occur-
rence of hemorrhage was adjusted for the mean age and the proportion of populations with
prior stroke or transient ischemic attack. In the adjusted analyses on thromboembolism, the
proportion of females was, furthermore, included.
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Results
Of 2169 papers, 35 papers met pre-specified inclusion criteria, holding relevant information
on 31 patient cohorts. In univariable meta-regression, increasing mean TTR was signifi-
cantly associated with a decreased rate of both major bleeding and stroke/systemic embo-
lism. However, after adjustment mean TTR was no longer significantly associated with
stroke/systemic embolism. The proportion of residual variance composed by between-study
heterogeneity was substantial for all analyses.
Conclusions
Although higher mean TTR in warfarin therapy was associated with lower complication rates
in atrial fibrillation, the strength of the association was decreased when adjusting for differ-
ences in relevant clinical characteristics of the patient cohorts. This study suggests that
mainly the safety of warfarin therapy increases with higher mean TTR, whereas effective-
ness appears not to be substantially improved.
Due to the limitations immanent in the meta-regression methods, the results of the pres-
ent study should be interpreted with caution. Further research on the association between
the quality of warfarin therapy and risk of complications is warranted with adjustment for clin-
ically relevant characteristics.
Introduction
Non-valvular atrial fibrillation (AF) is the most common cardiac arrhythmia with a prevalence as
high as 1.5–2.0% in the general population[1]. AF increases the risk of stroke substantially, why
effective stroke prophylaxis is vital[2]. Guidelines recommend continuous anticoagulation for the
majority of AF patients, either by non-vitamin K antagonist oral anticoagulants (NOACs) or vita-
min K antagonists, such as warfarin[2,3]. Particularly warfarin therapy may be challenging due to
a narrow therapeutic range; outside it, patients are exposed to an increased risk of either throm-
boembolism or hemorrhage. A generally accepted quality measure in warfarin therapy is the time
patients spend within the therapeutic range (percent time in therapeutic range; TTR)[3,4]. An
inverse correlation between TTR and hemorrhagic and thromboembolic complications has been
established and it has been suggested that the benefits of warfarin therapy may be outweighed if
the quality of warfarin therapy is too poor[5–8]. In continuation hereof, it may be beneficial to
increase TTR, if possible, as it would decrease the risk of therapy-related complications.
In addition, the risk of hemorrhage and thromboembolism also depends on patient charac-
teristics, such as sex, age, and prior bleeding and thromboembolism[2]. The presence of these
risk factors in a patient population may complicate the assumption of a ‘simple’ association
between the mean TTR of patient cohorts and complications as the relationship may be con-
founded by the clinical characteristics of the patient cohorts. The purpose of the present study
was to evaluate the association between mean TTR of AF patient populations on warfarin ther-
apy and the occurrence of patient-relevant outcomes through the execution of a systematic
review of randomized controlled trials (RCTs) and observational cohort studies and subse-
quent meta-regression. The analysis is conducted as a random-effects meta-regression, esti-
mating the effect of increasing mean TTR on complication rates with and without adjustment
for clinically relevant variables.
Meta-regression on the correlation between TTR in warfarin therapy and complications in AF
PLOS ONE | https://doi.org/10.1371/journal.pone.0188482 November 20, 2017 2 / 17
acted as consultant for Bayer. The other authors
declare no competing interests. This does not alter
our adherence to PLOS ONE policies on sharing
data and materials.
Materials and methods
Search strategy and eligibility criteria
A systematic review was performed of Embase and MEDLINE for papers published in the
period from January 2005 through 2015. The literature search was performed on 2 February
2016. The aim of the literature search and systematic review was to identify studies reporting
on use of warfarin therapy in patients with non-valvular AF and the occurrence of thrombo-
embolism and hemorrhage. The search strategy included use of thesaurus terms and explo-
sions of the same words. Additional studies were identified through prior knowledge of the
literature and snowballing on the reference lists of already acquired papers[5,9]. Eligible stud-
ies fulfilled the following inclusion criteria; full-text papers, in Danish or English, on RCTs or
observational cohort studies; both retrospective and prospective studies were included. When
multiple papers reported on the same patient cohort, the study with the greatest level of detail
on parameters of interest was included; for instance, a study reporting on complication rates
of multiple TTR strata would be chosen over another study on the entire cohort. Studies
should report on anticoagulation with dose-adjusted warfarin (target therapeutic range; inter-
national normalized ratio (INR) of 2–3) as the predominantly used vitamin K antagonist for
adult patients (age>18 years) with non-valvular AF as main indication. Studies on popula-
tions, of which a minor proportion of patients might have a concomitant indication for antico-
agulant therapy, such as deep venous thrombosis or other, were included. Studies on patients
with valvular AF were excluded as were studies in which complication rates were reported
aggregately for mixed populations, for instance for patients with valvular and non-valvular AF
combined. Quality of therapy should be reported by information on the study populations’
TTR. Studies reporting on specific subpopulations were excluded if generalizability of the
results to the broader AF population could not be expected, as were studies reporting on antic-
oagulation in relation to surgery or other therapies. Studies should include information on the
occurrence of thromboembolism and/or hemorrhage. Only studies with more than 50 persons
in each treatment group were included, and the mean follow-up time of patients should be
more than 3 months. The systematic review is reported in accordance with the PRISMA (Pre-
ferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines[10] (S1 Table.
PRISMA 2009 Checklist). The full electronic search strategy is shown in S2 Table. The ratio-
nale for the applied eligibility criteria is given in S3 Table.
Study selection and data extraction
The assessment of the eligibility of studies and data extraction was performed by the first author
(ASV) of the present study. Titles and abstracts of the identified papers were reviewed and papers
that did not meet the above-mentioned inclusion criteria were excluded. Papers deemed poten-
tially relevant by evaluation of the title and abstract were retrieved in full text for further assess-
ment. Papers were subsequently excluded if they did not meet the stated inclusion criteria based
on the full-text assessment. The following information was retrieved from studies; first author,
publication year, study setting; RCT versus ‘real-life’; i.e. anticoagulation clinic or community
practice (RCTs were defined as studies in which a randomization of patients into groups had
been performed, anticoagulation clinic were defined as studies undertaken at solely anticoagula-
tion clinics, but without randomization; community practice included all other studies), whether
the study was reported as being prospective or retrospective, geographical location of study
(North America, Europe including the United Kingdom, multinational, or ‘other’), total number
of patient-years, number of patients treated, method for estimation of TTR, mean age and TTR of
the patient population, characteristics of the study population in terms of proportion that was
Meta-regression on the correlation between TTR in warfarin therapy and complications in AF
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female, had prior stroke or transient ischemic attack (TIA), and that had a CHADS2 (Congestive
heart failure, hypertension age>75, diabetes mellitus, prior stroke, TIA, or systemic embolism
[doubled]) score of 0–1, 2, and 3+, respectively. When information on clinical characteristics was
provided for an entire study population, but event rates were stated for strata, the characteristics
of the entire study population were assumed for the strata.
For studies, in which the safety and effectiveness of warfarin were compared to that of
another oral anticoagulant agent, information was retrieved only for the group treated with
warfarin. Information on events was retrieved as rates, per 100 patient-years. All information
was retrieved as mean values or proportions, when possible. When median values were pro-
vided, these were assumed to be similar to the mean. When intervals for variables were given,
such as TTR and age, mean values for these were applied as point estimates. If relevant data
were not readily available in papers, they were estimated based on the provided data, for
instance, total number of patient-years was estimated by multiplying the number of patients
with the mean/median follow-up time per patient (Table 1). When necessary, event rates were
estimated based on total number of events and total follow-up time to allow comparability
between studies. Primary outcomes included major bleeding (MB) and stroke/systemic embo-
lism (SSE). In general, the definition of MB included intracranial and extracranial hemorrhage
requiring hospitalization, blood transfusion, surgical treatment, or when it occurred at a criti-
cal anatomical site. Supplementary analyses were performed for hemorrhagic stroke (HS) and
ischemic stroke (IS). For the present study, events were included as defined in papers.
Statistical analysis
Transformation was applied for the outcome rates, as they were non-Gaussian distributed. An
underlying binomial distribution of the rate was assumed as no event rates superseded 1. A
modified double arcsine transformation was chosen over the logit transformation to avoid oth-
erwise possible overdispersion caused by the rarity of events and to stabilize variances by
y ¼ 2  sin  1ð
ffiffiffiffiffiffiffiffi
rate
p
Þ
in which θ is the double arcsine transformed rate[11]. Standard errors of the transformed rates
were estimated as
SEy ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
1
ðpt year þ 0:5Þ
s
:
All analyses were performed on the double arcsine transformed rates. For illustrations,
results were back-transformed by
rate ¼ ðsin
y
2
Þ
2
and reported on the original scale.[11]
The risk of small-study effects and publication bias was assessed by inspection of funnel
plots of the effect size of studies against their estimated standard error within tertiles of mean
TTR of studies and Egger’s regression statistics for the same[12]. Between-study heterogeneity
was evaluated using the I2 statistics (including the Cochrane Q test p-value), for which an
I2>75% was considered to indicate a large degree of statistical heterogeneity[13].
The correlation between the reported mean TTR and the double arcsine transformed out-
come rates was evaluated by univariable, linear, random-effects meta-regressions with mean
TTR as the only predictor variable. In the random-effects meta-regression, the weight of
Meta-regression on the correlation between TTR in warfarin therapy and complications in AF
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studies, used to estimate the pooled effect size, is determined by within-study variance plus
between-study variance, equalizing the weights of larger and smaller studies[11,13]. The pro-
portion of the total variance explained by between-study heterogeneity was evaluated by the
I2res[13].
In addition, multivariable meta-regressions were performed to adjust for potential effect
modification or confounding with inclusion of a priori chosen relevant clinical covariates that
differ in real life patient cohorts [2,14]. In the meta-regressions on MB and HS, the impact of
mean TTR was adjusted for mean age and the proportion of populations with prior stroke or
TIA. In analyses on SSE and IS, the proportion of the study population that was female was,
furthermore, included. All covariates were assumed to have a continuous, linear effect. Studies
with missing information on the included covariates were excluded from the adjusted analyses.
As a result, univariable meta-regressions with mean TTR as single predictor were also per-
formed for the set of studies used in the adjusted analyses. Using the same regression basis,
this allowed for comparison of residual between-study heterogeneity in the uni- and multivari-
able meta-regressions. Permutation tests were performed for all multivariable meta-regres-
sions to adjust for multiplicity[14].
For supplementary analysis, the effect of mean TTR was adjusted for the impact of method-
ological variables by inclusion of covariates on publication year (grouped into years; 2005–
2007, 2008–2011, 2012–2015), setting (RCT, anticoagulation clinic, or community practice),
location (North America, European/UK, multinational, or other) and whether the study was
prospective, retrospective, or mixed.
2-tailed significance tests were used. Statistical significance was assumed for p-values<0.05,
except for Egger’s regression statistics for which a 0.1 threshold for significance was applied
[12]. All statistical analyses were performed using Stata/MP 13 (StataCorp LP, College Station,
TX). The meta-regressions were conducted using the Stata command ‘metareg’ with default
settings. The calculated standard errors of the transformed rates of individual studies were
employed as within-study standard error (‘wsse’).
Results
2144 papers were identified via Embase and 1664 papers were found via MEDLINE. 2169
papers remained after exclusion of duplicates. 17 papers were irretrievable and 16 papers were
found via other sources. To reduce the risk of missing relevant papers the results of the litera-
ture search were compared with those performed in previous studies with similar research
questions[5,9]. No discrepancies were found. 2089 papers were excluded based on their titles
and abstract, leaving 79 papers for full-text assessment of eligibility. Further 44 papers did not
meet the inclusion criteria, leaving 35 papers with relevant information for inclusion based on
31 patient cohorts; for 4 patient cohorts information was retrieved from different papers as
these held data on different outcomes of interest[6,15–20]. A flowchart of the study selection
and reasons for exclusions is given in Fig 1 [10].
Papers on 13 RCTs and 18 ‘real-life’ studies were included, of which 23 studies were prospec-
tive, seven studies were retrospective, and one was a combination. Six patient cohorts were from
North America, 12 from Europe/UK, 12 patient cohorts were multinational, and one was from
Turkey. In total, the patient cohorts included more than 100,000 patients with AF on warfarin
therapy. More papers reported on multiple treatment strata, which, henceforth, are treated as
individual studies. The unweighted estimated mean TTR of the studies was 64% [range: 25–
90%], the unweighted mean age was 74 years [range: 64–92], an unweighted average 21% [range:
0–58%] of populations had had a prior stroke/TIA, and included a mean of 41% [range: 0–100%]
women. Study characteristics are seen in Table 1.
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Publication bias was indicated for the 3rd (highest) tertiles of mean TTR for SSE (p = 0.07),
HS (p = 0.10), and IS (p = 0.01) by Egger’s regression statistics, though the basis for analysis
was small for HS and IS (number of studies <10). Slight asymmetry was observed for the
Fig 1. Flowchart of literature search and study exclusions. Adapted from Liberati et al. 2009[10]. Numbers in parenthesis in the lowermost
box indicate the number of studies included in random-effects multivariable meta-regressions. Four papers[16,18,19,21] on the same patient
cohort were retained as they held information on outcomes of interest not reported in the otherwise included papers on that patient cohort
[6,15,17,22].
https://doi.org/10.1371/journal.pone.0188482.g001
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funnel plots for MB in the 1st and 2nd tertiles of mean TTR, but was not confirmed by Egger’s
regression statistics (see S1 Fig). Missing information on prior stroke/TIA was deciding for
whether studies could be included in the adjusted analyses. There were no statistically signifi-
cant differences in outcome rates, mean TTR, number of patient-years, or mean age between
the studies that were included in adjusted analyses and those that were not.
50 studies, i.e. strata, reported on MB rates. In the univariable meta-regression with mean
TTR as only predictor for MB, mean TTR was negatively and statistically significantly corre-
lated with the arcsine transformed rate of MB (Fig 2A; p<0.01; Table 2). The proportion of
residual variance explained by between-study heterogeneity was high (I2res = 89.6%)[13]. 41
studies reported on all relevant clinical covariates and were included in the multivariable
meta-regression. Mean TTR remained significantly correlated with the transformed MB rate,
when adjusting for clinically relevant variables (p = 0.03; Table 2) and the proportion of the
residual variance caused by between-study heterogeneity was lower (I2res = 83.5%). In the
Fig 2. Bubble plots including fitted regression lines. Fitted meta-regression models with mean TTR as predictor of outcomes, respectively
hemorrhagic stroke, ischemic stroke, major bleeding, and stroke/systemic embolism. Circles are sized inversely proportionally to the estimated within-
study variance of effect reported in studies. The dashed line indicates the fitted regression line. S2 Fig supplies illustration of study weights applied in the
random-effects meta-regressions. HS: Hemorrhagic stroke, IS: Ischemic stroke, MB: Major bleeding, SSE: Stroke/systemic embolism, TTR: Time in
therapeutic range.
https://doi.org/10.1371/journal.pone.0188482.g002
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univariable meta-regression on the studies included in the adjusted analysis (N = 41), the cor-
relation between mean TTR and the MB rate was in general agreement with the impact
observed in the primary univariable meta-regression (Table 2).
33 studies reported on SSE. Increasing mean TTR was significantly associated with a
decrease in SSE in the univariable meta-regression (Fig 2B; p<0.01; Table 2). Residual variance
explained by between-study heterogeneity was considerable (I2res = 65.9%). 31 studies com-
posed the basis for the multivariable meta-regression. After adjustment, mean TTR was no
longer significantly correlated with SSE (p = 0.69; Table 2), but the proportion of residual vari-
ance caused by between-study heterogeneity was decreased (I2res = 43.2%). The results from
the univariable meta-regression on the studies included in the multivariable meta-regression
(N = 31) was similar to the primary univariable meta-regression on all studies (Table 2).
Supplementary analyses
28 studies held information on HS. Upon univariable meta-regression mean TTR was not
associated with HS and the proportion of residual variance explained by between-study het-
erogeneity was considerable (Fig 2C; p = 0.81; Table 2; I2res = 69.6%). 25 studies on HS held
information allowing for multivariable meta-regression, but adjusting for presence of prior
stroke/TIA and mean age, did not change the results (p = 0.85; Table 2; I2res = 60.1%). Results
of the univariable meta-regression on the 25 studies were in agreement with the primary uni-
variable meta-regression results (Table 2).
30 studies reported on IS. In the univariable meta-regression, mean TTR was negatively,
borderline significantly correlated with the double arcsine transformed IS rate (Fig 2D;
p = 0.05; Table 2). 24 studies were available for multivariable meta-regression. After adjust-
ment, the correlation remained insignificant (p = 0.40; Table 2). The proportion of residual
variance caused by between-study heterogeneity was high in both the uni- and multivariable
Table 2. Results of univariable and multivariable random-effects meta-regressions of the impact on
outcomes of mean time in therapeutic range.
Outcome* Meta-regression analysis Regression basis, N I2res TTR coefficient,
95% CI
Univariable 50 89.6% -0.0029 [-0.0048; -0.0009] †
MB Univariable‡ 41 82.7% -0.0017 [-0.0034;-0.0000] †
Multivariable 41 83.5% -0.0019 [-0.0036;-0.0002] †
Univariable 33 65.9% -0.0012 [-0.0020;-0.0004] †
SSE Univariable‡ 31 66.5% -0.0012 [-0.0020;-0.0004] †
Multivariable 31 43.2% -0.0002 [-0.0009;0.0006] -
Univariable 28 69.6% 0.0003 [-0.0020;0.0025] -
HS Univariable‡ 25 71.5% 0.0004 [-0.0022;0.0030] -
Multivariable 25 69.1% 0.0002 [-0.0017;0.0021] -
Univariable 30 94.4% -0.0032 [-0.0065;0.0000] -
IS Univariable‡ 24 94.4% -0.0022 [-0.0060;0.0016] -
Multivariable 24 92.7% -0.0015 [-0.0051;0.0021] -
CI: Confidence interval, HS: Hemorrhagic stroke, IS: Ischemic stroke, MB: Major bleeding, SSE: Stroke/
systemic embolism, TTR: Time in therapeutic range
*double arcsine transformed rate of outcome
†p<0.05
‡ Univariable meta-regression with mean TTR as only predictor, performed on the subset of studies used in
the multivariable meta-regression
https://doi.org/10.1371/journal.pone.0188482.t002
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meta-regression (I2res = 94.3% and 92.7%, respectively). The results from the univariable meta-
regression on studies reporting on all relevant covariates (N = 24) were in general agreement
with the results of the primary univariable meta-regression (Table 2).
When adjusting for multiplicity in the multivariable meta-regression on MB, mean TTR
remained significantly, negatively correlated with the occurrence of MB[14]. When including
relevant clinical and methodological covariates in the meta-regressions, mean TTR was signifi-
cantly correlated only with the transformed MB rate (p = 0.02) and statistical heterogeneity
remained for all outcomes (MB I2res = 64.7%, SSE I2res = 33.8%, HS I2res = 67.0%, IS I2res =
91.8%; see S4 Table).
The predicted association between mean TTR and MB and SSE rates from the univariable
and multivariable meta-regressions are illustrated in Fig 3A and 3B, respectively. In the
adjusted analyses, the predicted correlation between mean TTR and both outcomes is more
modest compared to the predicted correlation from the unadjusted analyses.
Discussion
To our knowledge, this is the first study to evaluate the association between mean TTR and
outcomes with adjustment for the clinical characteristics of the patient populations. As
expected, increasing mean TTR is associated with a decreasing rate of MB and SSE. The princi-
pal findings are that the association is markedly weakened when taking into account differ-
ences in relevant clinical characteristics of the included patient cohorts, i.e. mean age, the
proportion with prior stroke/TIA, and proportion female of the population, when relevant.
Furthermore, the main benefit of increasing mean TTR of a patient population would be
reached by lower rates of MB, whereas the effect of increasing mean TTR on the rate of SSE
appeared to be limited.
The included papers were published in the period 2005–2015, for which reason patient
cohort and treatment characteristics may be assumed to be similar to what may be expected in
2017, thereby likely increasing homogeneity for these parameters and the relevance of the
study[50,51].
Fig 3. Association between mean time in therapeutic range and rate of major bleeding and stroke/systemic embolism, predicted from uni- and
multivariable meta-regressions. Predicted rates of major bleeding and stroke/systemic embolism based on meta-regression with mean TTR as predictor
based on univariable (black lines) and multivariable (grey lines) meta-regression. For the predicted rates based on multivariable meta-regression, the
unweighted mean values from studies were used for age, proportion with prior stroke/transient ischemic attack, and proportion females. Vertical lines
indicate estimated 95% confidence intervals. MB: Major bleeding, SSE: Stroke/systemic embolism, TTR: Time in therapeutic range.
https://doi.org/10.1371/journal.pone.0188482.g003
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There appears to be a ‘publication skewness’ with markedly more studies reporting on the
safety outcome MB, compared to the effectiveness outcome SSE. This could be an indication
of a greater interest in research on safety issues than on effectiveness, though SSE may be
equally as devastating as MB. The existence of more papers on MB may also be an explanatory
factor, why only analyses found mean TTR to be a significant predictor for this outcome in the
adjusted meta-regression model. The availability of fewer studies decreases the robustness of
analyses and impedes the establishment of associations[13]. For both IS and HS it could be
hypothesized that too few studies were available for meta-regression and the validity of these
models is discussable.
The present analyses are based on study level covariates and results are therefore potentially
valid only for patient cohorts. Thus, the present analyses do not necessarily reflect the correla-
tion between mean TTR and outcomes for individual patients, but may be used to e.g. estimate
the possible benefit of increasing mean TTR for entire patient cohorts. The adjusted models
only account for cohorts with characteristics within the value ranges of the used studies. The
present results are intended to reflect a broad AF population, including, amongst other, new-
starters[23,29] and the very old[39,47], who are known to be at a greater risk of complications
than experienced warfarin users and younger patients[8,9]. These subgroups are a part of the
AF patient population for whom treatment strategies are decided. Therefore, they should be
included in models concerning the association between quality in warfarin therapy for the gen-
eral AF population and complications. The generalizability of the study results to specific sub-
groups is discussable.
According to Sandén et al.[44], the rate of complications during warfarin therapy does not
correlate to TTR of centers when the mean TTR is above 70%. Cancino et al.[52] have found
the same lack of correlation at high TTRs. As the correlation has been confirmed for data sets
with lower TTR levels[7,8,52], this could suggest that the association between mean TTR and
complication rates might not be completely linear. In the present model, the double arcsine
transformation of the rates was used to normalize the data and stabilize variances. However, in
consequence, the predicted association on the original scale is also slightly nonlinear (Fig 3),
which agrees with the hypothesis of a nonlinear association.
The present paper suffers from a number of limitations. One author (ASV) performed the
literature search, evaluated the papers, and excluded studies based on the pre-specified inclu-
sion criteria. This entails the possibility that some studies have been missed and that studies
have been erroneously excluded. Likewise, the data extraction was performed by a single
author. Optimally, these tasks should have been undertaken or validated by more authors[10].
The purpose of this study was to accumulate relevant information and evaluate the association
between mean TTR of patient populations on warfarin therapy and outcomes, for which rea-
son no formal quality assessment of studies was performed in relation to the present literature
review, nor were studies excluded due to insufficient quality. Study design could be hypothe-
sized to affect outcomes[9], but supplementary analyses including methodological covariates
did not affect results substantially (see S4 Table). The inclusion of different study designs may
be a contributory factor to the high level of between-study heterogeneity observed in this
study. However, focusing on e.g. RCTs to decrease between-study heterogeneity would unset-
tle the foundation of the meta-regression substantially, for which reason this restriction was
opted out of.
The definition of outcomes and reporting differ in studies, which hampers their compara-
bility. To allow for meta-regression, the definition of outcomes was used as applied in studies
and assumptions were imposed on, for instance, data equivalency and transferability. This
likely decreases the validity of the results, and may be an explanatory factor for the high degree
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of uncertainty pertaining to the results and the large proportion of statistical heterogeneity
composed by residual between-study heterogeneity.
A pragmatic approach was taken to the inclusion of covariates in the adjusted meta-regres-
sions, balancing data availability with the request to include all relevant information. Only
including a subset of relevant clinical covariates in the meta-regressions most likely subjects
the results to unobserved confounding. However, inclusion of more clinically relevant vari-
ables would cause the exclusion of further studies in the adjusted analyses, rendering the basis
for the present analysis unsound.
Despite the substantial degree of between-study heterogeneity, population characteristics
were relatively similar across the included studies, which, in fact, complicates the establish-
ment of correlations between the covariates and outcomes. If a greater dispersion of values for
covariates were observed, associations might have been easier to establish. With the present
dataset, the resulting coefficients and associated uncertainty may be susceptible to the inclu-
sion of new studies if their data are dissimilar to the data used in the present analysis. The
results presented here are based on study level covariates and as such may be subject to eco-
logical bias. The use of aggregate data should incite caution when interpreting the results.[14]
However, the association between the covariates used in the adjusted analyses and outcomes
has previously been established and the tendencies here are in general agreement with prior
findings[2,8]. The uncertainty introduced by ecological fallacy in the present study might be
clarified in future analysis, if patient-level data are available[14].
In 2008, Wan et al.[5] performed a systematic review and linear regression analysis on the
relationship between TTR and MB and thromboembolism. In agreement with the results by
Wan et al., our study indicated a significant inverse correlation between TTR and MB, even
when adjusting for differences in patient cohort characteristics. Wan et al.[5] also found a sig-
nificant inverse relationship between TTR and thromboembolisms. As the present study applied
an associated outcome, SSE, the same inverse relationship was expected and confirmed in the
univariable meta-regression, but could not be found when adjusting for patient cohort charac-
teristics. The present study includes more studies and takes a different analytical approach to
the interpretation of the data by application of the random-effects meta-regression model,
which may explain the differences in results.
Cancino et al.[52] have shown differences in the predictive ability of center-level and indi-
vidual-level mean TTR for complications with individual-level mean TTR being the superior
predictor. Individual-level mean TTR may be more appropriate for prediction of complication
rates, but center-level mean TTR may still be of use for evaluation of quality improvements
[52]. In the present study, no distinction was made between mean TTR summarized at patient-
or center-level. Future research based on individual patient-level data may allow for prediction
of the impact of improving quality in warfarin therapy with adjustment for differences in
patient characteristics and clarify any potential similarities to the models presented here.
Other indicators of quality in warfarin therapy exist that have been linked to the clinical
outcomes of patients in warfarin therapy, including the proportion of INR measurements that
are within the therapeutic range[53], information on the variability in INR measurements[54],
and patterns of anticoagulation control[7]. These indicators of quality in warfarin therapy may
also warrant further investigation, as they may provide the basis for improved prediction mod-
els for complications during therapy. However, currently, none of these measures have
achieved the same widespread use as an indicator of quality in warfarin therapy as the TTR.
In conclusion, mean TTR was inversely and significantly associated with both the occur-
rence of MB and SSE in the univariable random-effects meta-regression. However, the
strength of the association was markedly decreased when adjusting for differences in relevant
clinical cohort characteristics. After adjustment, mean TTR remained significantly correlated
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only with the rate of MB. The present study suggests that increasing quality in warfarin ther-
apy, i.e. increasing mean TTR for patient groups with AF, mainly affects the safety of therapy
by decreasing the rate of MB, whereas the rate of SSE does not seem to be substantially reduced
with increasing mean TTR. Clinical cohort characteristics should be taken into consideration
when evaluating the impact of mean TTR in warfarin therapy on complications. Excluding
these from analyses may bias the expected association between mean TTR and outcomes and,
for instance, inflate the benefits of increasing quality in warfarin therapy by increasing mean
TTR for a patient population, if an ‘optimistic’ correlation is expected.
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